Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NaF/FDG PET/MRI for Xofigo Response in mCRPC
NCT02429804Phase 1Terminated
- Sponsor
- Stanford University
- Start
- Apr 2015
- Primary completion
- May 2017
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of radium-223 dichloride in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Stanford University. Primary endpoints: Dichotomized treatment response at 24 weeks, based on technetium Tc-99m medronate (99mTc-MDP) bone scintigraphy intensity, Dichotomized treatment response at 24 weeks, based on computed tomography (CT) lesion size and 3 more. Started Apr 2015; status: terminated.
02
Drugs
radium-223 dichloride
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02429804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02429804.